Hernia Sac Flap Coverage of Mesh in Bony-Edged Ventral Hernia Repair

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorMinia University

About this trial

This trial asks whether covering the inner, bowel-facing surface of a hernia mesh with a flap of the patient's own hernia sac improves healing after repair of a complex ventral (abdominal wall) hernia in which one edge of the defect is bone - for example hernias next to the breastbone and ribs, above the pubic bone, or at the iliac crest.

In these "bony-edged" hernias the mesh is both hardest to fix and hardest to cover. There is no fascia on the bony side for the surgeon to stitch the mesh to, and the lining layer of the abdomen cannot be closed underneath the mesh because the plane that carries it stops at the bone. The mesh may therefore be left in contact with the bowel, which can lead to dense adhesions, mesh erosion, chronic pain and, rarely, a fistula.

Normally the hernia sac - the thin membrane that lines the hernia - is cut away and discarded. In this trial the surgeon instead preserves it as a living, blood-supplied flap, rotates it underneath the mesh, and stitches it in place as a new lining layer that separates the mesh from the bowel and covers the bony edge. The technique uses only the patient's own tissue: no extra mesh, no donor site and no added cost.

One hundred and eighty adults undergoing planned (non-emergency) open repair of a bony-edged complex ventral hernia will be randomly assigned in equal numbers to one of two groups: standard retromuscular (sublay) mesh repair with the added sac flap (90 participants), or standard retromuscular mesh repair alone, with the sac handled in the conventional way (90 participants). Every other step of the operation is the same in both groups.

The main question is whether the sac flap reduces the number of participants who develop any wound or mesh problem in the first 30 days after surgery. This is measured as a composite called a surgical site occurrence, which includes wound infection, seroma, haematoma, skin or soft-tissue death, wound breakdown, mesh exposure and fistula. The trial also compares complications needing a drainage or operative procedure, hernia recurrence at 12 months, overall complication severity, operating time, blood loss, hospital stay, readmission, reoperation, pain, quality of life and death.

Participants, ward and clinic staff, the doctors who assess the wounds, the radiologist who reads the follow-up scans and the trial statistician will not know which operation was performed; only the operating surgeon will. The group assignment is revealed only during the operation, after the surgeon has confirmed that the defect truly has a bony edge and that the sac is suitable for a flap. Participants are followed for 12 months.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 18 years or older.

Elective open repair planned for a complex ventral hernia (primary or incisional) in which at least one margin of the fascial defect is formed by bone - that is, a subxiphoid or costal-margin, suprapubic, or iliac or lumbar location - confirmed on cross-sectional imaging (CT or MRI) and at operation.

A hernial sac of sufficient quality and surface area to raise a pedicled flap adequate to cover the planned mesh, as judged at operation.

Planned retromuscular (sublay) synthetic mesh repair, with or without posterior component separation (transversus abdominis release).

Disqualifiers

Emergency or urgent operation (incarceration with strangulation, obstruction, or perforation).

Active intra-abdominal infection, or a contaminated or dirty operative field (CDC wound class III-IV) at the time of randomization.

Planned use of biologic or composite intraperitoneal mesh, or a bridged (non-fascial-closure) repair as the primary plan.

Hernial sac absent, destroyed, densely scarred, or too small to raise a viable covering flap.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Sac-flap peritonealization of the mesh

    Procedure/Surgery

    The hernial sac is not excised. After reduction of the hernia contents, a broad flap of the sac is preserved on its vascular pedicle. Before the mesh is fixed, the flap is rotated deep to the prosthesis and sutured circumferentially with a slow-absorbable suture to form a continuous neo-peritoneal layer that fully separates the visceral surface of the mesh from the abdominal contents. At the bony margin, the leading edge of the flap is anchored across the bone - to periosteum, to the contralateral posterior layer, or with trans-osseous or peri-osteal sutures as anatomy permits - providing soft-tissue coverage and a buttress where fascial fixation is impossible. Hemostasis of the flap is confirmed and a closed-suction drain is placed in the retromuscular space. No additional prosthetic material and no donor site are used.

  • Retromuscular (sublay) synthetic mesh repair

    Procedure/Surgery

    Open repair through a midline or location-appropriate incision, with reduction of hernia contents and adhesiolysis as required; definition of the fascial defect including the bony margin, with measurement of defect width and length and recording of the European Hernia Society location and size class; development of the retromuscular (retrorectus) plane, with posterior component separation by transversus abdominis release where required to achieve tension-free closure; placement of a flat, medium-weight monofilament polypropylene mesh of standardized type in the retromuscular position with wide overlap and standardized suture fixation; anterior fascial closure of the linea alba where achievable; and closed-suction retromuscular drainage. This intervention is common to both arms and is delivered identically in each.

Treatment groups

180 Participants
are divided into 2 treatment groups
Group A: Sac-flap peritonealization + retromuscular mesh repairExperimental treatment 1 intervention
Group B: Standard retromuscular mesh repairActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Composite surgical site occurrence (SSO)

Proportion of participants experiencing one or more components of the composite: surgical site infection (per CDC criteria), seroma, hematoma, skin or soft-tissue necrosis, wound dehiscence, mesh exposure, or enterocutaneous fistula. The outcome is binary (present/absent) at the participant level. It is assessed by independent masked outcome assessors using a structured wound proforma with photographic documentation; each component is also recorded individually, with its date of onset and management, so that components can be analyzed separately and so that the subset requiring procedural intervention can be derived.

Time frame
Within 30 days after surgery

Secondary outcomes

1

Surgical site occurrence requiring procedural intervention (SSOPI)

Proportion of participants with a surgical site occurrence that requires percutaneous drainage, opening of the wound, or operative debridement.

Time frame
30 days and 90 days after surgery
2

Hernia recurrence

Proportion of participants with a clinically detected bulge or fascial defect, confirmed on physical examination and cross-sectional imaging (CT or MRI) read by a masked radiologist, or confirmed at reoperation.

Time frame
6 months and 12 months after surgery
3

Overall morbidity: highest Clavien-Dindo grade

The highest Clavien-Dindo grade of postoperative complication recorded for each participant. The scale runs from Grade I (any deviation from the normal postoperative course not requiring pharmacological, surgical, endoscopic or radiological intervention) to Grade V (death of the patient); a higher grade indicates a more severe complication.

Time frame
30 days and 90 days after surgery
4

Overall morbidity: Comprehensive Complication Index (CCI)

The Comprehensive Complication Index summarizes all postoperative complications for each participant on a continuous scale from 0 (no complication) to 100 (death). Higher scores indicate greater cumulative postoperative morbidity.

Time frame
30 days and 90 days after surgery

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.